“Long-Term Efficacy of Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: Data from a Pivotal Phase 3 Clinical Trial”, J of Skin, vol. 2, no. S1, p. S9, Feb. 2018, doi: 10.25251/skin.2.supp.9.